Zynex — Investor Presentation (March 2011)
16 slides from Zynex's investor presentation, Mar 7, 2011
Slide 1: March 2011 1
March 2011 1
Slide 2: Forward Looking Statements
March 2011 2 Forward Looking Statements Statements made in this presentation include financial estimates and forward-looking statements that are not historical facts. Each of these estimates and forward-looking statements involves risk and uncertainties. These estimates are based on present circumst
Slide 3: Business Highlights
March 2011 3 Business Highlights Publicly Traded OTCBB: ZYXIIn operation since 1996Primary current business- Manufacturer of Electrotherapy home pain management devices (billed to insurance) Helped over 100,000 patients since inceptionHigh growth 54% CAGR since 1996>70%+ recurring revenue (>40,000 u
Slide 4: Business Structure
March 2011 4 Business Structure 100% of Revenue In Development
Slide 5: Zynex Medical-Existing Business Revenue
March 2011 5 Zynex Medical-Existing Business Revenue 1,000's 96 97 98 99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10* Revenue 36 211 491 552 911 1190 1387 1084 1256 2300 3500 8000 11700 18681 24085 54% CAGR *2010 estimated revenue based on Q4 guidance given on Nov 8, 2010
Slide 6: Zynex Medical-Existing Business
March 2011 6 Zynex Medical-Existing Business Barrier to entry for most Zynex-focus on customer service Zynex-proven system/process Continued geographic expansion for growth More units in field = greater recurring revenue
Slide 7: History
History Founded by Thomas Sandgaard with his own capital as a wholesaler of ze TENS electrotherapy pain management devices 1999 First Zynex-manufactured device cleared by FDA 2001 | _ Shifted from wholesale-only to direct sales to physicians/end-users and billing insurance carriers 2003 | Fillline o
Slide 8: Strategic Direction of New Subsidiaries ("the Future")
March 2011 8 Strategic Direction of 2 New Subsidiaries ("the Future") (ZMS) Monitoring Solutions:Cardiovascular Monitoring, such as Blood Volume Monitoring during surgery, in the recovery room, etc.Patent filed, prototyping well under way (positive results)Complementary technology acquisitions plann
Slide 9: Current & Future Markets
March 2011 9 Current & Future Markets ~$550M ~$1.5B ~$700M TAM ~ 2.7B
Slide 10: Zynex's Long-Term Goal
March 2011 10 Zynex's Long-Term Goal Become a strong, global Medical Device playerFocus on products/applications with high GPM'sRecurring revenue growth Only take calculated risksManage balance sheetCash flow positiveContinue high growth with a mix of acquisitions/organic based on valuation=stock pr
Slide 11: Creating Shareholder Value
March 2011 11 Creating Shareholder Value NowGet off the OTCBBWorking toward listing on AMEX/Nasdaq$3.5M Line of Credit in place for current growth (~$1.0 borrowed)Drive Revenue and Earnings Growth with existing business! 1-2 Years OutAcquisitions to rapidly grow 2 new subsidiariesIntroduce new produ
Slide 12: Corporate & Ownership Structure
March 2011 12 Corporate & Ownership Structure Common Stock: 30,600,000 shares outstandingLimited overhang, only 1,800,000 in employee stock options and 80,000 warrantsAuditors: GHP Horwath, PCCorporate Counsel: Faegre & Benson LLPBOD: T. Simonton, M. Vitale, M. Wahlstrom, T. Sandgaard Thomas Sandgaa
Slide 13: March 2011 13
March 2011 13
Slide 14: Highlights
March 2011 14 Highlights Historical growth 54% CAGR (existing ZMED)Established recurring revenue stream (40k+ units in field)Strong balance sheet (very little debt)Significant opportunity in new subs (ZMS, ZND)Additional $2.2B marketWorking toward listing on AMEX/Nasdaq No capital needed until we st
Slide 15: Contact Info
March 2011 15 CONTACT INFO: For more information, please contact:Anthony [email protected] Zynex, Inc.9990 Park Meadows DriveLone Tree, CO 80124Telephone: (303) 703-4906 Facsimile: (303) 347-9153www.zynexmed.com
Slide 16: Stock symbol: ZYXI
March 2011 16 Stock symbol: ZYXI